Last reviewed · How we verify
Experimental: Protesomal Vaccine 1 x 30 µg
Experimental: Protesomal Vaccine 1 x 30 µg is a Biologic drug developed by Hvivo. It is currently in Phase 1 development.
At a glance
| Generic name | Experimental: Protesomal Vaccine 1 x 30 µg |
|---|---|
| Sponsor | Hvivo |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Development of an Intranasal Proteosome Influenza Vaccine (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental: Protesomal Vaccine 1 x 30 µg CI brief — competitive landscape report
- Experimental: Protesomal Vaccine 1 x 30 µg updates RSS · CI watch RSS
- Hvivo portfolio CI
Frequently asked questions about Experimental: Protesomal Vaccine 1 x 30 µg
What is Experimental: Protesomal Vaccine 1 x 30 µg?
Experimental: Protesomal Vaccine 1 x 30 µg is a Biologic drug developed by Hvivo.
Who makes Experimental: Protesomal Vaccine 1 x 30 µg?
Experimental: Protesomal Vaccine 1 x 30 µg is developed by Hvivo (see full Hvivo pipeline at /company/hvivo).
What development phase is Experimental: Protesomal Vaccine 1 x 30 µg in?
Experimental: Protesomal Vaccine 1 x 30 µg is in Phase 1.